Drug conjugate comprising quinoline derivatives
US12172965B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Sep 17, 2019 |
| Grant date | Dec 24, 2024 |
| Priority date | — |
| Expiry date | Dec 15, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D215/48
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compounds having the formula (I): wherein R1 represents a group: —NH2, —NHCORa, —NHCOORb, —(C2-C6)alkenylene-CO—NH—OH, —(C2-C6)alkynylene-CO—NH—OH or —OH; R2 represents a group: —OCH3, —OCH2CH3, —SCH3, —SCH2CH3 or —OCHF2; R3 represents a hydrogen atom or a group: —CH3, —CN, —F, —Cl or —ORc; R4 represents a hydrogen atom or a group: —CH3, —CN, —F, —Cl or —ORd; Ra represents a group: —(C1-C5)alkyl or —CF3; Rb represents a group: —(C1-C5)alkyl or —CF3; Rc represents a group: —(C1-C5)alkyl or —CF3; and Rd represents a group: —(C1-C5)alkyl or —CF3; in the state of a base or acid or acid salts or base salts or in the form of hydrate or of solvate. Also disclosed are drug conjugates including such compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.